204 related articles for article (PubMed ID: 33370973)
1. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe.
Barbaro D; Lapi P; Viacava P; Torregrossa L
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33370973
[TBL] [Abstract][Full Text] [Related]
2. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.
Sugitani I; Onoda N; Ito KI; Suzuki S
J Nippon Med Sch; 2018; 85(1):18-27. PubMed ID: 29540641
[TBL] [Abstract][Full Text] [Related]
3. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
4. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Cancer Chemother Pharmacol; 2018 Oct; 82(4):649-654. PubMed ID: 30051190
[TBL] [Abstract][Full Text] [Related]
5. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive anaplastic thyroid carcinoma: report of a case and literature review.
Dibelius G; Mehra S; Clain JB; Urken ML; Wenig BM
Thyroid; 2014 Aug; 24(8):1319-24. PubMed ID: 24865498
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
Fan D; Ma J; Bell AC; Groen AH; Olsen KS; Lok BH; Leeman JE; Anderson E; Riaz N; McBride S; Ganly I; Shaha AR; Sherman EJ; Tsai CJ; Kang JJ; Lee NY
Cancer; 2020 Jan; 126(2):444-452. PubMed ID: 31593317
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic Thyroid Carcinoma Treated with Lenvatinib.
Ohkubo JI; Takahashi A; Ikezaki S; Takenaga F; Ohkubo Y; Suzuki H
Kurume Med J; 2018 Feb; 64(1.2):29-33. PubMed ID: 29057760
[TBL] [Abstract][Full Text] [Related]
10. Case Report: 84-Month Disease-Free Survival after Surgery for Anaplastic Thyroid Carcinoma.
Kanazawa S; Kammori M
J Nippon Med Sch; 2019; 86(1):38-42. PubMed ID: 30918155
[TBL] [Abstract][Full Text] [Related]
11. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case.
Juhlin CC; Höög A
Int J Surg Pathol; 2019 Sep; 27(6):658-663. PubMed ID: 30931661
[TBL] [Abstract][Full Text] [Related]
12. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
13. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.
Luongo C; Porcelli T; Sessa F; De Stefano MA; Scavuzzo F; Damiano V; Klain M; Bellevicine C; Matano E; Troncone G; Schlumberger M; Salvatore D
Curr Oncol; 2021 Dec; 28(6):5401-5407. PubMed ID: 34940089
[TBL] [Abstract][Full Text] [Related]
14. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
[No Abstract] [Full Text] [Related]
15. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
[TBL] [Abstract][Full Text] [Related]
16. Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma.
Gay S; Monti E; Trambaiolo Antonelli C; Mora M; Spina B; Ansaldo G; Teliti M; Comina M; Conte L; Minuto M; Varaldo E; Zupo S; Massa B; Morbelli S; Giusti M
Future Oncol; 2019 Aug; 15(24s):13-19. PubMed ID: 31385546
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic thyroid carcinoma with rhabdoid phenotype: An unusual case and a comprehensive review.
Bansal S; Sancheti S; Kaur S; Somal P; Kalra SK; Sali AP
Diagn Cytopathol; 2020 Nov; 48(11):1125-1130. PubMed ID: 32515545
[TBL] [Abstract][Full Text] [Related]
18. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
Hamamoto T; Kono T; Taruya T; Ishino T; Ueda T; Takeno S
Auris Nasus Larynx; 2022 Jun; 49(3):515-519. PubMed ID: 33109426
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.
Sheu NW; Jiang HJ; Wu CW; Chiang FY; Chiou HC; Hsiao PJ
World J Surg Oncol; 2019 May; 17(1):84. PubMed ID: 31103041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
